Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Advanced Solid Tumors
NCT05143970Phase 1Active, not recruiting
- Sponsor
- Institut Paoli-Calmettes
- Start
- Jan 2022
- Primary completion
- Mar 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IPH5301 in solid tumor, breast cancer, pancreatic cancer (PC) and 5 more, sponsored by Institut Paoli-Calmettes. Primary endpoint: Dose Limiting Toxicity at 1 month. Started Jan 2022; status: active, not recruiting.
02
Drugs
IPH5301
03
Conditions
solid tumorbreast cancerpancreatic cancer (PC)gastric cancer (GC)lung cancer
Beyond the preview
Go deeper on NCT05143970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05143970.